haysmacintyre, Chartered Accountants and tax advisers, acted as reporting accountants for Medgenics Inc as they raised £3.28 million in their Initial Public Offering in conjunction with their listing on AIM in December 2007.

Medgenics Inc, a US based company with a wholly owned subsidiary in Israel, is a biopharmaceutical company developing a unique, tissue-based “Biopump” platform technology to provide sustained action protein therapy for the treatment for a range of chronic diseases.

haysmacintyre partner, Ian Cliffe, believes the firm was appointed due to its experience and expertise in acting as reporting accountants for overseas entities.

“We are excited to be working with Medgenics Inc. and believe their company has great potential for growth in a very short time scale”, he said.

haysmacintyre advises listed companies – both with a full listing and on the Alternative Investment Market (AIM).  It has recently assisted a number of companies achieve their AIM listing, many of which were from outside the UK.

-ends-

For more information please contact:
Sarah Bannister, haysmacintyre  020 7969 5575

ABOUT HAYSMACINTYRE

haysmacintyre, Chartered Accountants and tax advisers, comprises 24 partners and 150 staff based in Holborn, London. It provides high quality auditing and assurance, business and personal taxation, corporate finance, financial planning and other business support services.

haysmacintyre is a founding member of MSI Global Alliance (MSI), an international alliance of independent legal and accounting firms, with 250 members in 100 countries.

ABOUT HAYSMACINTYRE CORPORATE FINANCE

The haysmacintyre corporate finance team has much experience in advising small and medium sized companies on the full range of corporate finance issues such as: acquisitions, loans, disposals, financial reporting and management systems, flotations, management buy-outs and buy-ins, mergers, private equity, public offers, raising finance and taxation.

haysmacintyre also advises several listed companies – both with a full listing and those on the Alternative Investment Market (AIM).